FDA

First Opinion S. Bryn Austin and Amanda Raffoul

A new Trump administration will further loosen already-lax rules on supplements

Politics STAT Staff

STAT Plus: What can Trump and RFK Jr. actually do on health care?

Morning Rounds Brittany Trang

Escaped monkeys and who to know in the MAHA world

Health Lizzy Lawrence and Timmy Broderick

What Trump and Robert F. Kennedy Jr. might do to undermine vaccines — and what they likely can’t

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

How a Trump presidency could affect the FDA, the biotech industry, and its stocks

First Opinion Carmel Shachar

STAT Plus: A second Trump administration will accelerate the undermining of the medical profession

Who to Know Katie Palmer

STAT Plus: These 6 companies are using AI to streamline clinical trials for pharma

Who to Know Isabella Cueto

STAT Plus: ‘MAHA’ is moving into Trump’s White House. Here’s who RFK Jr. could bring along for the ride 

Politics Lizzy Lawrence

STAT Plus: What letting RFK Jr. ‘go wild’ might mean for Trump’s FDA

Politics Sarah Owermohle

STAT Plus: Donald Trump returns to the presidency with big ambitions to shake up health care

Health Anil Oza

Lawsuit to fix pulse oximeter bias makes progress with device manufacturers

Pharmalot Ed Silverman

STAT Plus: To mitigate drug shortages, a new study suggests looking at Canada

First Opinion Neil Stollman

Fecal transplants are saving lives — but are now at risk

D.C. Diagnosis Sarah Owermohle

STAT Plus: D.C. Diagnosis: Why is Kamala Harris headed to Texas?

Adam's Take Adam Feuerstein

STAT Plus: Elon Musk bungles his criticism of U.S. drug regulators

Biotech Elaine Chen

STAT Plus: Novo asks FDA to bar compounders from making Ozempic copies

Exclusive Lizzy Lawrence

STAT Plus: Michelle Tarver to lead FDA medical device center

Morning Rounds Theresa Gaffney

Morning Rounds: RFK fears, an ‘epic’ FDA fight, Marburg update

Health Kathryn Kranhold

STAT Plus: Former FDA lawyers join tobacco industry in ‘epic’ fight against the agency

First Opinion Peter J. Pitts

STAT Plus: The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Politics Lizzy Lawrence

STAT Plus: Ahead of public meeting, FDA signals flexibility in evaluating smoking cessation treatments

Health Elizabeth Cooney

STAT Plus: Q&A: FDA chief on why our hearts are less healthy, how obesity drugs impress him, and what worries him

Letters to the editor Torie Bosch

First Opinion readers on Covid and Trump, rare diseases, and institutional neutrality

Pharma Katie Palmer

STAT Plus: In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list

Health tech Katie Palmer

STAT Plus: Q&A: How the FDA is approaching AI in clinical trials and drug development

Opinions+ Emil D. Kakkis

STAT Plus: Traditional randomized trials don’t work for ultra-rare diseases like Barth syndrome

Exclusive Matthew Herper

STAT Plus: Janet Woodcock, former FDA official, joins board of patient group focused on ‘rediscovering’ old drugs

Biotech Jonathan Wosen

STAT Plus: Exact Sciences wins FDA approval for improved stool-based colon cancer test

Health tech Usha Lee McFarling and Lizzy Lawrence

STAT Plus: FDA misses target date for releasing recommendations to make pulse oximeters more equitable